Results 221 to 230 of about 49,828 (259)

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 168-177, July 2026.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

DPPPRED-IV: An Ensembled QSAR-Based Web Server for the Prediction of Dipeptidyl Peptidase 4 Inhibitors. [PDF]

Int J Mol Sci
Carpio LE, Olivares M, Ortega-Vallbona R, Serrano-Candelas E, Sanz Y, Gozalbes R.   +5 more
europepmc   +1 more source

Serum Advanced Glycation End Products as Drivers of Poor Tendon Outcomes in Diabetes? An Emerging Hypothesis and Narrative Review

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Tendon injuries in diabetes heal poorly, with unclear drivers of extracellular matrix disruption and altered mechanics. This narrative review synthesizes in vitro, animal, and human studies, highlighting serum advanced glycation end products as potential systemic contributors.
Eric J. Gutierrez, Lauren E. Mitevski, Jacob M. Haus, Chad C. Carroll   +3 more
wiley   +1 more source

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]

Cureus
Prakash V, Goel N.
europepmc   +1 more source

Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study (REVISE Study)

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
ICTI to evogliptin from other DPP‐4 inhibitors significantly improved glycemic control in patients with type 2 diabetes inadequately controlled on metformin‐based therapy. The treatment was well tolerated, supporting ICTI as a pragmatic optimization strategy in routine clinical practice. ABSTRACT Aims While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are
Jie‐Eun Lee, Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jong Chul Won   +14 more
wiley   +1 more source

Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis. [PDF]

Curr Ther Res Clin Exp
Tuersun A, Cui S, Han L, Aikebaier A, Shi Y, Cheng G, Cheng L, Ma G.   +7 more
europepmc   +1 more source

Preparation and Hypoglycemic Activity of Enzymatically Hydrolyzed Peptides From the Swim Bladder of Pangasius bocourti

Food Science &Nutrition, Volume 14, Issue 7, July 2026.
Fish swim bladder is a low‐value byproduct from Pangasius bocourti processing. Herein, we successfully prepared hypoglycemic bioactive peptides from P. bocourti swim bladder (PBSBPs) via optimized alkaline protease hydrolysis. Peptidomic analysis revealed abundant low‐molecular‐weight peptides rich in hydrophobic amino acids with predicted α ...
Ju Yang, Xu Qiu, Huan Zhang, Kefeng Wu, Yushuang Li, Guangxin Xu, Jianlin He, Junde Chen, Xixiang Tang   +8 more
wiley   +1 more source

Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection. [PDF]

Int J Ophthalmol
Chung YR, Kim C, Lee E, Lee K.
europepmc   +1 more source

Salivary Extracellular Vesicles: Paradigm Shift in Liquid Biopsy Diagnostics

Journal of Extracellular Biology, Volume 5, Issue 7, July 2026.
ABSTRACT Extracellular vesicles (EVs), lipid bilayer nanoparticles released by virtually all cells, serve as essential messengers for intercellular communication. Due to their involvement in several pathophysiological processes, EVs have recently gained considerable attention as potentially diagnostic and prognostic biomarkers for various illnesses ...
Kwanele Xulu, Usri H. Ibrahim, Irene Mackraj, Carola Niesler   +3 more
wiley   +1 more source

Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. [PDF]

Sci Rep
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source